Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection.

@article{Hosaka2013LongtermET,
  title={Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection.},
  author={Tetsuya Hosaka and Fumitaka Suzuki and Masahiro Kobayashi and Yuya Seko and Yusuke Kawamura and Hitomi Sezaki and Norio Akuta and Yoshiyuki Suzuki and Satoshi Saitoh and Yasuji Arase and Kenji Ikeda and Mariko Kobayashi and Hiromitsu Kumada},
  journal={Hepatology},
  year={2013},
  volume={58 1},
  pages={98-107}
}
UNLABELLED Chronic hepatitis B virus (HBV) infection leads to cirrhosis and hepatocellular carcinoma (HCC). Antiviral agents are thought to reduce HCC development, but agents such as lamivudine (LAM) have a high rate of drug resistance. We compared the incidence of HCC in 472 entecavir (ETV)-treated patients and 1,143 nontreated HBV patients (control group). Propensity score matching eliminated the baseline differences, resulting in a sample size of 316 patients per cohort. The drug mutation… CONTINUE READING
Highly Influential
This paper has highly influenced 11 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 8 times over the past 90 days. VIEW TWEETS
206 Citations
29 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 206 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Similar Papers

Loading similar papers…